Report #2830591

Received Mar 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (2)

FatigueMyalgia

Symptom narrative

Fatigue; experienced myalgia; This non-serious case was reported by a physician via sales rep and described the occurrence of fatigue in a elderly patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 1st dose of Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced fatigue (Verbatim: Fatigue) and myalgia (Verbatim: experienced myalgia). The outcome of the fatigue was resolved and the outcome of the myalgia was not reported. The reporter considered the fatigue to be related to Arexvy. It was unknown if the reporter considered the myalgia to be related to Arexvy. The company considered the fatigue to be related to Arexvy. It was unknown if the company considered the myalgia to be related to Arexvy. Additional Information: GSK Receipt Date: 05-MAR-2025 Physician reported that patient took Arexvy vaccine and experienced fatigue and myalgia.